Skip to main content
EJNMMI Research

Table 1 Participant characteristics

From: A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

Subject no

Age (years)

Histology

Stage

IHC score* (CNB)

SISH

IHC score† (excision)

Neoadjuvant chemotherapy

History of Trastuzumab treatment

Interval from CNB to 64Cu-NOTA-Trastuzumab (months)

Tumor size (cm)

1

45

IDC

IV

3+ 

N/A

N/A

–

–

1

7.3

2

42

IDC

IIIB

3+ 

N/A

3+ 

AC #3

–

2

2.4

3

46

IDC

IIIA

3+

N/A

1+

AC #4

–

3

1.7

4

45

IDC

IIA

–

N/A

–

AC #4

–

3

2.2

5

56

IDC

IIIB

2+

–

1+

AC #4

–

3

14.0

6

54

IDC

IIB

–

N/A

–

AC #3

–

2

4.6

  1. IHC immunohistochemistry, SISH silver-enhanced in situ hybridization, CNB core needle biopsy, IDC invasive ductal carcinoma, N/A not applicable, AC anthracycline, and cyclophosphamide
  2. *IHC score with core needle biopsy at the initial diagnosis
  3. †IHC score with tumor excision after neoadjuvant chemotherapy
Back to article page